MX2015010115A - Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos. - Google Patents
Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.Info
- Publication number
- MX2015010115A MX2015010115A MX2015010115A MX2015010115A MX2015010115A MX 2015010115 A MX2015010115 A MX 2015010115A MX 2015010115 A MX2015010115 A MX 2015010115A MX 2015010115 A MX2015010115 A MX 2015010115A MX 2015010115 A MX2015010115 A MX 2015010115A
- Authority
- MX
- Mexico
- Prior art keywords
- depleting
- antibodies
- methods
- red blood
- blood cell
- Prior art date
Links
- 210000003743 erythrocyte Anatomy 0.000 title abstract 2
- 230000000779 depleting effect Effects 0.000 title 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 abstract 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 abstract 2
- 230000004520 agglutination Effects 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/024995 WO2013119714A1 (en) | 2012-02-06 | 2013-02-06 | Cd47 antibodies and methods of use thereof |
| US13/761,087 US9045541B2 (en) | 2012-02-06 | 2013-02-06 | CD47 antibodies and methods of use thereof |
| US201361815219P | 2013-04-23 | 2013-04-23 | |
| PCT/US2013/053818 WO2014123580A1 (en) | 2013-02-06 | 2013-08-06 | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010115A true MX2015010115A (es) | 2016-05-31 |
Family
ID=51300031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010115A MX2015010115A (es) | 2013-02-06 | 2013-08-06 | Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos. |
| MX2021008851A MX2021008851A (es) | 2013-02-06 | 2015-08-04 | Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008851A MX2021008851A (es) | 2013-02-06 | 2015-08-04 | Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos. |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP2953643B1 (enExample) |
| JP (2) | JP2016507555A (enExample) |
| KR (2) | KR102276974B1 (enExample) |
| CN (1) | CN105101997B (enExample) |
| AU (2) | AU2013377886B2 (enExample) |
| BR (1) | BR112015018851A2 (enExample) |
| CA (1) | CA2900468C (enExample) |
| CL (1) | CL2015002203A1 (enExample) |
| EA (1) | EA036963B1 (enExample) |
| ES (1) | ES2944477T3 (enExample) |
| IL (2) | IL240390B (enExample) |
| MX (2) | MX2015010115A (enExample) |
| NI (1) | NI201500103A (enExample) |
| NZ (1) | NZ710695A (enExample) |
| PE (1) | PE20151408A1 (enExample) |
| PH (1) | PH12015501729A1 (enExample) |
| SG (2) | SG10201706383XA (enExample) |
| WO (1) | WO2014123580A1 (enExample) |
| ZA (2) | ZA201505745B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2812443B1 (en) | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| HK1216647A1 (zh) | 2012-12-12 | 2016-11-25 | Vasculox Inc. | 治疗性cd47抗体 |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| HUE047221T2 (hu) | 2012-12-17 | 2020-04-28 | Trillium Therapeutics Inc | A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal |
| AU2014238105B2 (en) | 2013-03-15 | 2018-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-CD47 agents |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| WO2016081423A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| TWI719966B (zh) * | 2015-03-04 | 2021-03-01 | 美商索倫多醫療公司 | 結合ｃｄ４７之抗體治療劑 |
| CA2993835A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| CN108348589B (zh) * | 2015-09-18 | 2022-09-23 | 安驰肿瘤公司 | 治疗性cd47抗体 |
| CA2999277A1 (en) | 2015-09-21 | 2017-03-30 | Surface Oncology, Inc. | Anti-cd47 antibodies and methods of use |
| KR102472087B1 (ko) * | 2016-01-11 | 2022-11-29 | 포티 세븐, 인코포레이티드 | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 |
| RS66062B1 (sr) | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| CN117695387A (zh) | 2016-04-15 | 2024-03-15 | 小利兰·斯坦福大学托管委员会 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
| US11649284B2 (en) | 2016-04-18 | 2023-05-16 | Baylor College Of Medicine | Cancer gene therapy targeting CD47 |
| CN106084052B (zh) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| CN106117354B (zh) * | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗CD47的全分子IgG抗体及其应用 |
| EA201990218A1 (ru) | 2016-07-06 | 2019-07-31 | Селджин Корпорейшн | Антитела с низкой иммуногенностью и их применения |
| US10277886B2 (en) | 2016-07-19 | 2019-04-30 | Gopro, Inc. | Mapping of spherical image data into rectangular faces for transport and decoding across networks |
| CN107955071B (zh) * | 2016-10-18 | 2021-03-26 | 上海赛远生物科技有限公司 | 人源抗人cd47抗体及其编码基因与应用 |
| KR102423086B1 (ko) | 2016-10-20 | 2022-07-20 | 아이-맵 바이오파마 유에스 리미티드 | 새로운 cd47 단일클론 항체 및 그 용도 |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| EP3532497B1 (en) * | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| WO2018081897A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| US11779631B2 (en) | 2016-11-03 | 2023-10-10 | Pfizer Inc. | CD47 blockade therapy by HDAC inhibitors |
| WO2018089508A2 (en) | 2016-11-08 | 2018-05-17 | Ablexis, Llc | Anti-cd47 antibodies |
| CN108779179B (zh) * | 2016-11-28 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | Cd47抗体、其抗原结合片段及其医药用途 |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| US11267885B2 (en) | 2017-01-26 | 2022-03-08 | Zlip Holding Limited | CD47 antigen binding unit and uses thereof |
| SG11201908602UA (en) * | 2017-03-22 | 2019-10-30 | Arch Oncology Inc | Combination therapy for the treatment of solid and hematological cancers |
| CN110612309A (zh) * | 2017-03-27 | 2019-12-24 | 细胞基因公司 | 用于降低免疫原性的方法和组合物 |
| PT3642242T (pt) | 2017-06-21 | 2024-04-16 | Univ Leland Stanford Junior | Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas |
| NZ761568A (en) * | 2017-08-02 | 2022-11-25 | Phanes Therapeutics Inc | Anti-cd47 antibodies and uses thereof |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| WO2019084692A1 (en) | 2017-11-06 | 2019-05-09 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
| WO2019091449A1 (zh) * | 2017-11-10 | 2019-05-16 | 江苏恒瑞医药股份有限公司 | Cd96抗体、其抗原结合片段及医药用途 |
| CN110573622A (zh) * | 2017-11-10 | 2019-12-13 | 天境生物科技(上海)有限公司 | 包含cd47抗体和细胞因子的融合蛋白 |
| US11891450B2 (en) | 2018-02-12 | 2024-02-06 | Forty Seven, Inc. | Anti-CD47 agent-based treatment of CD20-positive cancer |
| CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| EP3802602A1 (en) | 2018-05-25 | 2021-04-14 | Alector LLC | Anti-sirpa antibodies and methods of use thereof |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| TWI830774B (zh) * | 2018-08-31 | 2024-02-01 | 大陸商南京聖和藥業股份有限公司 | 抗cd47抗體及其應用 |
| AU2019336345A1 (en) | 2018-09-04 | 2021-04-15 | Pfizer Inc. | CD47 blockade with parp inhibition for disease treatment |
| MX2021004779A (es) * | 2018-10-31 | 2021-06-08 | I Mab Biopharma Us Ltd | Anticuerpos cd47 novedosos y metodos para usarlos. |
| TW202104260A (zh) | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合ｃｄ４７之抗體之工程 |
| WO2020247820A1 (en) | 2019-06-07 | 2020-12-10 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN113461817B (zh) * | 2020-03-31 | 2025-04-18 | 苏州泽璟生物制药股份有限公司 | 一种抗人cd47抗体及其抗原结合片段、制备方法和应用 |
| TWI869582B (zh) * | 2020-04-10 | 2025-01-11 | 大陸商和記黃埔醫藥（上海）有限公司 | 抗ｃｄ４７抗體及其用途 |
| CN116171284A (zh) * | 2020-04-24 | 2023-05-26 | 维尔托索宾科公司 | 用于治疗cd47相关疾病的双特异性抗体 |
| CN120040592A (zh) * | 2020-07-31 | 2025-05-27 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス，インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| TW202413428A (zh) * | 2020-12-23 | 2024-04-01 | 大陸商廣東菲鵬製藥股份有限公司 桃園路1號10棟301室 郵編：523808 | 靶向cd47的抗體、編碼其的核酸、包含其的載體、細胞、藥物組合物、其應用及其試劑盒 |
| EP4276113A4 (en) * | 2021-01-08 | 2025-04-09 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to CD47 and antigen-binding fragment thereof |
| MX2023010916A (es) | 2021-03-17 | 2023-12-14 | Myeloid Therapeutics Inc | Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas. |
| US20240423983A1 (en) | 2021-04-27 | 2024-12-26 | Pf Argentum Ip Holdings Llc | Enhancement of cd47 blockade therapy with dhfr inhibitors |
| CA3218780A1 (en) | 2021-05-11 | 2022-11-17 | Daniel Getts | Methods and compositions for genomic integration |
| US20250235504A1 (en) | 2021-10-29 | 2025-07-24 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| WO2023079438A1 (en) | 2021-11-08 | 2023-05-11 | Pfizer Inc. | Enhancement of cd47 blockade therapy with anti-vegf agents |
| CN118221812A (zh) * | 2022-12-14 | 2024-06-21 | 上海迈石生物技术有限公司 | 一种靶向cd47的单克隆抗体及其应用 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994000569A1 (en) | 1992-06-18 | 1994-01-06 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| EP0703979B1 (en) | 1993-06-04 | 2000-09-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method for treating kaposi's sarcoma with antisense oligonucleotides |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE69636868T2 (de) | 1995-08-29 | 2007-10-25 | Kirin Beer Kabushiki Kaisha | Chimäres tier und methode zu dessen herstellung |
| US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| WO1999055369A1 (en) * | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| TWI241345B (en) * | 2000-03-10 | 2005-10-11 | Chugai Pharmaceutical Co Ltd | Apoptosis inducing polypeptide |
| WO2002092784A2 (en) * | 2001-05-15 | 2002-11-21 | Emory University | POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47 |
| EP1575509B1 (en) * | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| US8101719B2 (en) * | 2003-11-11 | 2012-01-24 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-CD47 antibody |
| BRPI0819693A2 (pt) * | 2007-11-30 | 2020-08-18 | Glaxo Group Limited | Construção de ligação de antígeno, método para tratar um paciente que sofre de câncer ou uma doença inflamatória, sequência de polinucleotídeo, polinucleotídeo, célula hospedeira transformada ou transfectada recombinante, método para produziruma construção de ligação de antígeno, e, composição farmacêutica |
| US8420784B2 (en) * | 2008-05-27 | 2013-04-16 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor, (IL-10R) antibodies |
| KR101781965B1 (ko) * | 2008-08-14 | 2017-09-27 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-ｉｌ-12/ｉｌ-23 항체 |
| DK2569013T3 (da) * | 2010-05-14 | 2017-02-13 | Univ Leland Stanford Junior | Humaniserede og kimære monoklonale antistoffer til cd47 |
| BR112013024574B1 (pt) * | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| EP2812443B1 (en) * | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2013
- 2013-08-06 EA EA201500818A patent/EA036963B1/ru not_active IP Right Cessation
- 2013-08-06 MX MX2015010115A patent/MX2015010115A/es unknown
- 2013-08-06 BR BR112015018851A patent/BR112015018851A2/pt not_active Application Discontinuation
- 2013-08-06 CN CN201380075409.3A patent/CN105101997B/zh active Active
- 2013-08-06 EP EP13874383.6A patent/EP2953643B1/en active Active
- 2013-08-06 SG SG10201706383XA patent/SG10201706383XA/en unknown
- 2013-08-06 EP EP22185286.6A patent/EP4137518A1/en active Pending
- 2013-08-06 CA CA2900468A patent/CA2900468C/en active Active
- 2013-08-06 KR KR1020207030070A patent/KR102276974B1/ko active Active
- 2013-08-06 NZ NZ710695A patent/NZ710695A/en unknown
- 2013-08-06 PE PE2015001628A patent/PE20151408A1/es active IP Right Grant
- 2013-08-06 WO PCT/US2013/053818 patent/WO2014123580A1/en not_active Ceased
- 2013-08-06 KR KR1020157024103A patent/KR102170196B1/ko active Active
- 2013-08-06 JP JP2015556930A patent/JP2016507555A/ja active Pending
- 2013-08-06 SG SG11201506132PA patent/SG11201506132PA/en unknown
- 2013-08-06 ES ES13874383T patent/ES2944477T3/es active Active
- 2013-08-06 AU AU2013377886A patent/AU2013377886B2/en active Active
-
2015
- 2015-08-04 MX MX2021008851A patent/MX2021008851A/es unknown
- 2015-08-06 NI NI201500103A patent/NI201500103A/es unknown
- 2015-08-06 IL IL240390A patent/IL240390B/en active IP Right Grant
- 2015-08-06 CL CL2015002203A patent/CL2015002203A1/es unknown
- 2015-08-06 PH PH12015501729A patent/PH12015501729A1/en unknown
- 2015-08-11 ZA ZA2015/05745A patent/ZA201505745B/en unknown
-
2018
- 2018-08-03 JP JP2018146460A patent/JP6726238B2/ja active Active
-
2019
- 2019-02-11 AU AU2019200942A patent/AU2019200942B2/en active Active
- 2019-08-12 ZA ZA2019/05292A patent/ZA201905292B/en unknown
-
2020
- 2020-05-10 IL IL274566A patent/IL274566B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501729A1 (en) | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof | |
| PH12014501758A1 (en) | Cd47 antibodies and methods of use thereof | |
| PH12017500915A1 (en) | Cd47 antibodies, methods, and uses | |
| PH12016501908A1 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
| EA201590528A1 (ru) | Антитела к мсам и способы их применения | |
| PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
| NZ703423A (en) | Antibodies to tau | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
| EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
| MX2019001355A (es) | Anticuerpos monoclonales multiespecíficos. | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| MX2014012978A (es) | Regiones de anticuerpo modificado y sus usos. | |
| EA201690992A1 (ru) | Антитела, специфичные к fcrn | |
| ZA201703510B (en) | Antibodies, uses & methods | |
| SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
| MX2014014381A (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
| MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| GB201207155D0 (en) | Antibodies | |
| EA201691112A1 (ru) | Образование антител ex vivo | |
| NZ743971A (en) | Antibodies to tau |